These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27213499)

  • 21. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
    Epperla N; Fenske TS; Lazarus HM; Hamadani M
    Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations with newer regimens for indolent non-Hodgkin lymphoma.
    Rummel M
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S128-36. PubMed ID: 18952543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
    Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR; Bonavida B
    Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized management of follicular lymphoma.
    Bai B; Huang HQ
    Chin Clin Oncol; 2015 Mar; 4(1):7. PubMed ID: 25841714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are we nearing an era of chemotherapy-free management of indolent lymphoma?
    Bachy E; Salles G
    Clin Cancer Res; 2014 Oct; 20(20):5226-39. PubMed ID: 25320372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clearing minimal residual disease with rituximab consolidation therapy.
    Brugger W
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.
    Cohen Y; Solal-Céligny P; Polliack A
    Haematologica; 2003 Jul; 88(7):811-23. PubMed ID: 12857561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radioimmunotherapy of follicular lymphoma: a step towards cure?].
    Ketterer N; Bischof Delaloye A; Helg C; Luthi F; Buchegger F
    Bull Cancer; 2007 Sep; 94(9):799-806. PubMed ID: 17878100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early stage follicular lymphoma, current management and controversies.
    Jacobson CA; Freedman AS
    Curr Opin Oncol; 2012 Sep; 24(5):475-9. PubMed ID: 22820411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
    Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The current status and future impact of targeted therapies in non-Hodgkin lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Hematol; 2013 Apr; 6(2):191-202; quiz 203. PubMed ID: 23547867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
    Lazzarino M; Arcaini L; Orlandi E; Iacona I; Bernasconi P; Calatroni S; Varettoni M; Isa L; Brusamolino E; Bonfichi M; Passamonti F; Burcheri S; Pascutto C; Regazzi M
    Oncology; 2005; 68(2-3):146-53. PubMed ID: 16006752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance therapy in follicular lymphoma.
    Michallet AS; Coiffier B; Salles G
    Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
    McLaughlin P
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.